Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment

References

• UNAIDS fact sheet 2018 [cited 2018 Nov 20]. Available from: http://www.unaids.org/en/resources/fact-sheet
   Google Scholar
• Lange J, Ananworanich J. The discovery and development of antiretroviral agents. Antivir Ther. 2014;19(Suppl 3):5–14.
   Google Scholar
• Mayer KH, Venkatesh KK. Antiretroviral therapy as HIV prevention: status and prospects. PubMed PMID: 20724682 Am J Public Health. 2010;10010:1867–1876.
   Google Scholar
• FDA. Antiretroviral drugs used in the treatment of HIV infection 2018 [cited 2018 Nov 20]. Available from: https://www.fda.gov/forpatients/illness/hivaids/treatment/ucm118915.htm
   Google Scholar
• De Clercq E. Antiretroviral drugs. Curr Opin Pharmacol. 2010 Jan 10;10(5):507–515.
   Google Scholar
• De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr 01;33(4):307–320.
   Google Scholar
• Stolbach A, Paziana K, Heverling H, et al. A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol. 2015;11(3):326–341. PubMed PMID: 26036354.
   Google Scholar
• DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [Cited 2019 Nov 20]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
   Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013 Jan 01;138(1):103–141.
   Google Scholar
• Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol. 2007;3(4):583–598.
   Google Scholar
• Dooley KE, Charles F, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;198(7):948–961.
   Google Scholar
• Granfors MT, Wang J-S, Kajosaari LI, et al. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five Human Immunodeficiency Virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan 01;98(1):79–85.
   Google Scholar
• Hossain MA, Tran T, Chen T, et al. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. J Pharm Pharmacol. 2017 Dec 01;69(12):1786–1793.
   Google Scholar
• Wyen C, Fuhr U, Frank D, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther. 2008 Jul 01;84(1):75–82.
   Google Scholar
• Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. PubMed PMID: 9278209 Br J Clin Pharmacol. 1997;442:190–194.
   Google Scholar
• Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet. 2007 Sep 01;46(9):739–756.
   Google Scholar
• Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacother J Human Pharmacol Drug Ther. 2004;24(12):1732–1747.
   Google Scholar
• Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clin Pharmacokinet. 1998 Oct 01;35(4):275–291.
   Google Scholar
• Schöller-Gyüre M, Kakuda TN, Raoof A, et al. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009 Sep 01;48(9):561–574.
   Google Scholar
• Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 1997 Mar 15;11(4):F29–F33. PubMed PMID: 9084785.
   Google Scholar
• NNORVIR® (ritonavir). [Package insert]. North Chicago, (IL): Abbvie Inc.; 2017.
   Google Scholar
• Petruschke RA, Zeldin RK. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):4–9.
   Google Scholar
• Sabo JP, Norris SH, Johnson P, et al. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers AU - MacGregor, Thomas R. HIV Clin Trials. 2004 Dec 01;5(6):371–382. .
   Google Scholar
• Kurowski M, Kaeser B, Sawyer A, et al. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Ther. 2002 Aug 01;72(2):123–132. .
   Google Scholar
• KALETRA® (lopinavir/ritonavir).  [Package insert]. North Chicago, (IL): Abbvie Inc.; 2015.
   Google Scholar
• APTIVUS® (tipranavir).  [Package insert]. Germany: Boehringer Ingelheim, Ingelheim am Rhein; 2018.
   Google Scholar
• Orman JS, Perry CM. Tipranavir. Drugs. 2008 Jul 01;68(10):1435–1463.
   Google Scholar
• Salazar JC, Cahn P, Della Negra M, et al. Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience. Pediatr Infect Dis J . 2014;33(4):396–400. PubMed PMID: 00006454-201404000-00017.
   Google Scholar
• Larson KB, Wang K, Delille C, et al. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet. 2014 Oct 01;53(10):865–872. .
   Google Scholar
• TYBOST® (cobicistat). [Package insert]. Foster City, (CA): Gilead Sciences, Inc.; 2018.
   Google Scholar
• GENVOYA® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide). [Package insert]. Foster City, (CA): Gilead Sciences, Inc.; 2015.
   Google Scholar
• Molina J-M, LaMarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012 Jan 01;12(1):27–35. .
   Google Scholar
• Deeks ED. Cobicistat: A Review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb 01;74(2):195–206.
   Google Scholar
• Marzolini C, Back D, Gibbons S, et al. Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71(7):1755–1758.
   Google Scholar
• Ramanathan S, Custodio JM, Wei X, et al. Pharmacokinetics of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate after switch from efavirenz/emtricitabine/tenofovir disoproxil fumarate in healthy subjects. J Acquir Immune Defic Syndr. 2016;72(3):281–288. PubMed PMID: 00126334-201607010-00008.
   Google Scholar
• Tseng A, Hughes CA, Wu J, et al. Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences. Ann Pharmacother. 2017;51(11):1008–1022. PubMed PMID: 28627229.
   Google Scholar
• LEXIVA® (fosamprenavir calcium).  [Package insert]. Research Triangle Park, (NC): GlaxoSmithKline; 2009.
   Google Scholar
• Lewi DS, Suleiman JM, Uip DE, et al. Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3. Rev Inst Med Trop São Paulo. 2000;42(1):27–36.
   Google Scholar
• Fogo AB, Lusco MA, Najafian B, et al. AJKD atlas of renal pathology: indinavir nephrotoxicity. Am J Kidney Dis. 2017 Jan;69(1):e3. PubMed PMID: 28007196; eng.
   Google Scholar
• CRIXIVAN® (indinavir sulfate). [Package insert]. Kenilworth, (NJ): Merck; 2018.
   Google Scholar
• VIRACEPT® (nelfinavir mesylate).  [Package insert]. New York City, (NY): Pfizer; 2016.
   Google Scholar
• Pai VB, Nahata MC. Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother. 1999 Mar 01;33(3):325–339.
   Google Scholar
• Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother. 2001;45(4):1086–1093. PubMed PMID: 11257019.
   Google Scholar
• Raines CP, Flexner C, Sun E, et al. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. J Acquired Immune Deficiency Syndromes. 1999– 2000;25(4):322–328.
   Google Scholar
• PREZISTA® (darunavir). [Package insert]. Titusville, (NJ): Janssen Therapeutics, Inc.; 2016.
   Google Scholar
• PREZCOBIX® (darunavir and cobicistat). [Package insert]. Titusville, (NJ): Janssen Therapeutics, Inc.; 2018.
   Google Scholar
• Kakuda TN, Brochot A, Tomaka FL, et al. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. J Antimicrob Chemother. 2014 Oct;69(10):2591–2605. PubMed PMID: 24951533.
   Google Scholar
• Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013 Jan;14(1):49–59. PubMed PMID: 23088336.
   Google Scholar
• Kakuda TN, Van De Casteele T, Petrovic R, et al. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. Antivir Ther. 2014;19(6):597–606. PubMed PMID: 24964392.
   Google Scholar
• REYATAZ® (atazanavir). [Package insert]. Princeton, (NJ): Bristol-Myers Squibb Company; 2018.
   Google Scholar
• Goutelle S, Baudry T, Gagnieu M-C, et al. Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients. Antimicrob Agents Chemother. 2013;57(1):517–523. PubMed PMID: 23147727.
   Google Scholar
• Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016 Jun 01;18: 50–56.
   Google Scholar
• INVIRASE® (saquinavir mesylate). [Package insert]. Basel, Switzerland: Roche; 2018.
   Google Scholar
• ClinicalTrials.gov. A randomized, parallel arm, comparative, open label, multicenter study of the activity and safety of two formulations of saquinavir in combination with other antiretroviral drugs 2005. [Cited 2018 Nov 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT00002162
   Google Scholar
• SUSTIVA® (efavirenz). [Package insert]. New York City, (NY): Bristol-Myers Squibb Pharma Company;2016.
   Google Scholar
• INTELENCE®. (etravirine). [Package insert]. Titusville (NJ): Janssen Products; 2008.
   Google Scholar
• Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS. 2007;21(6):F1–10.
   Google Scholar
• Grunfeld C. Dyslipidemia and its Treatment in HIV Infection. J Med Toxicol. 2010 Aug-Sep;18(3):112–118. PubMed PMID: 20921577.
   Google Scholar
• Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008 Jul 01;47(7):463–474.
   Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16(4):569–577.
   Google Scholar
• Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017;8:6–14. PubMed PMID: 29067253.
   Google Scholar
• CDC. TB and HIV coinfection 2018. [Cited 2018 Nov 20]. Available from: https://www.cdc.gov/tb/topic/basics/tbhivcoinfection.htm
   Google Scholar
• Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006;5:3. PubMed PMID: 16480505.
   Google Scholar
• Khaliq Y, Gallicano K, Venance S, et al. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2000;68(6):637–646.
   Google Scholar
• Grub S, Bryson H, Goggin T, et al. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol. 2001;57(2):115–121.
   Google Scholar
• Polk RE, Crouch MA, Israel DS, et al. Pharmacokinetic Interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacother J Human Pharmacol Drug Ther. 1999;19(12):1378–1384.
   Google Scholar
• Siddiqi O, Birbeck GL. Safe treatment of seizures in the setting of HIV/AIDS. PubMed PMID: 23657845 Curr Treat Options Neurol. 2013;154:529–543.
   Google Scholar
• Bates DE, Herman RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann Pharmacother. 2006;40(6):1190–1195.
   Google Scholar
• Liegl CA, McGrath MA. Ergotism: case report and review of the literature. Int J Angiol. 2016;25(5):e8–e11. . PubMed PMID: 28031641.
   Google Scholar
• Baldwin ZK, Ceraldi CC. Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg. 2003;37(3):676–678.
   Google Scholar
• Petit E, Schoonheydt K, Meert P, et al. Drug-drug interaction of ergotamine with a combination of darunavir, abacavir, and lamivudine causing a fatal vasospastic ischemia. Case Rep Emerg Med. 2018;2018:4.
   Google Scholar
• Avihingsanon A, Ramautarsing RA, Suwanpimolkul G, et al. Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warning. Top Antivir Med. 2016;21(5):165–168. PubMed PMID: 24531557.
   Google Scholar
• Fröhlich G, Kaplan V, Amann-Vesti B. Holy fire in an HIV-positive man: a case of 21st-century ergotism. PubMed PMID: 20048008 Cmaj. 2010;1824:378–380.
   Google Scholar
• Zhou S-F, Liu J-P CB. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009 May 01;41(2):89–295.
   Google Scholar
• Swart M, Mpeta B, Wonkam A, et al. Cytochrome P450 pharmacogenetics in African populations: implications for public health AU - Dandara, Collet. Expert Opin Drug Metab Toxicol. 2014 Jun 01;10(6):769–785.
   Google Scholar
• Kodidela S, Pradhan SC, Dubashi B, et al. Influence of dihydrofolate reductase gene polymorphisms rs408626 (−317A>G) and rs442767 (−680C>A) on the outcome of methotrexate-based maintenance therapy in South Indian patients with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2015 Nov 01;71(11):1349–1358.
   Google Scholar
• Owen A, Siccardi M, Olagunju A, et al. Class-specific relative genetic contribution for key antiretroviral drugs. J Antimicrob Chemother. 2015;70(11):3074–3079.
   Google Scholar
• Neary M, Owen A. Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. Expert Opin Drug Metab Toxicol. 2017 Nov;13(11):1169–1181. PubMed PMID: 28994310; eng.
   Google Scholar
• Thompson EE, Kuttab-Boulos H, Witonsky D, et al. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet. 2004;75(6):1059–1069. PubMed PMID: 15492926.
   Google Scholar
• Berno G, Zaccarelli M, Gori C, et al. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs. BMC Med Genet. 2014;15:76. PubMed PMID: 24986243.
   Google Scholar
• Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15(1):1–5.
   Google Scholar
• Hofmann MH, Blievernicht JK, Klein K, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther. 2008;325(1):284–292.
   Google Scholar
• Liu X, Ma Q, Zhao Y, et al. Impact of single nucleotide polymorphisms on plasma concentrations of efavirenz and lopinavir/ritonavir in chinese children infected with the human immunodeficiency virus. Pharmacotherapy. 2017;37(9):1073–1080. PubMed PMID: 28718515.
   Google Scholar
• Gallien S, Journot V, Loriot MA, et al. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms: a substudy of the ANRS ALIZE trial. HIV Med. 2017 Sep 01;18(8):537–545.
   Google Scholar
• Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;61(4):914–918. PubMed PMID: 18281305.
   Google Scholar
• Singh H, Lata S, Nema V, et al. CYP1A1m1 and CYP2C9*2 and *3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity. APMIS. 2017 Jun 01;125(6):523–535.
   Google Scholar
• Zhu L, Brüggemann RJ, Uy J, et al. CYP2C19 genotype–dependent pharmacokinetic drug interaction between voriconazole and ritonavir-boosted atazanavir in healthy subjects. J Clin Pharmacol. 2017 Feb 01;57(2):235–246.
   Google Scholar
• Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: considerations for HIV treatment. PubMed PMID: 19663676 Pharmacogenomics. 2009;108:1323–1339.
   Google Scholar
• Roy U, Rodríguez J, Barber P, et al. The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine (Lond). 2015;10(24):3597–3609. PubMed PMID: 26400459.
   Google Scholar
• Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems [journal article]. J Occup Med Toxicol. 2007;2(1):16.
   Google Scholar
• Edagwa BJ, Zhou T, McMillan JM, et al. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem. 2014;21(36):4186–4198. PubMed PMID: 25174930; PubMed Central PMCID: PMCPMC4281174.
   Google Scholar
• Gong Y, Chowdhury P, Midde NM, et al. Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages. Biochem Biophys Rep. 2017;12:214–219.
   Google Scholar
• Fukushima K, Terasaka S, Haraya K, et al. Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system. Biol Pharm Bull. 2007;30(4):733–738.
   Google Scholar
• Singh G, Pai RS, Atazanavir-Loaded Eudragit RL. 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal. Drug Deliv. 2016;23(2):532–539.
   Google Scholar
• McKeage K, Perry CM, Keam SJ. Darunavir. Drugs. 2009;69(4):477–503.
   Google Scholar
• Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. Aids. 2007;21(6):F11–F18.
   Google Scholar
• Desai J, Thakkar H. Darunavir-Loaded Lipid Nanoparticles for Targeting to HIV Reservoirs. AAPS PharmSciTech. 2018;19(2):648–660.
   Google Scholar
• Augustine R, Ashkenazi DL, Arzi RS, et al. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination. Acta Biomater. 2018;74:344-359.
   Google Scholar
• Ong CE, Pung YF, Chieng JY. The current understanding of the interactions between nanoparticles and cytochrome P450 enzymes – a literature-based review AU - Pan, Yan. Xenobiotica. 2018;1–14. DOI:10.1080/00498254.2018.1503360
   Google Scholar
• Alam C, S-K W-A, Omeragic A, et al. Role and modulation of drug transporters in HIV-1 therapy. Adv Drug Deliv Rev. 2016;103:121–143.
   Google Scholar
• Griffin L, Annaert P, Brouwer KLR. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. PubMed PMID: 21698598 J Pharm Sci. 2011;1009:3636–3654.
   Google Scholar